Latest Conference Articles

Dr Wu on SAFFRON-301 Data in Advanced or Metastatic NSCLC

Yi-Long Wu, MD, PhD, discusses findings from the phase 3 SAFFRON-301 trial in patients with advanced or metastatic NSCLC.

Dato-DXd Misses OS End Point in TROPION-Lung01 Study for NSCLC

Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.

HS-20093 Generates Responses in Pretreated ES-SCLC

HS-20093 produced responses in extensive-stage small cell lung cancer after prior platinum-based chemotherapy with or without prior immunotherapy.

Frontline Amivantamab/Lazertinib Combo Shows Trend of OS Benefit in Advanced EGFR+ NSCLC

When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.

TROP2 Membrane Ratio Effectively Predicts Dato-DXd Outcomes in NSCLC

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

Dr Sen on Interim IDeate-Lung01 Data in Extensive-Stage SCLC

Triparna Sen, PhD, discusses findings from an interim analysis of the phase 2 IDeate-Lung01 trial in patients with extensive-stage small cell lung cancer.

Patient-Level Data Support Perioperative Nivolumab Use in Resectable NSCLC

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

Novel Perioperative Combinations Show Efficacy in Resectable NSCLC

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC

Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.

Dr Spira on Updated MARIPOSA Trial Data in EGFR+ Advanced NSCLC

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

Global Survey Examines Barriers to Optimal Lung Cancer Biomarker Testing

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes

Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.

Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma

Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.

Histologic Distinctions and Optimized Imaging Carve New Paths for Individualized PTCL Management

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma

The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.

Dr Seymour on the Role of Mutational Profiling in CLL

John Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia.

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL

Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

Improved OS, Cost Effectiveness Are Necessary to Shift Later-Line TKIs to Frontline CML-CP

Elias Jabbour, MD, discusses the potential activity and financial benefit of novel and emerging TKIs for first-line management of chronic phase CML.

Dr Merryman on the Evolution of MRD Assays in Lymphoma

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Dr Kebriaei on the Potential Shift Away From Transplant in ALL

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma

The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.

Imetelstat Delivers Sustained RBC-TI With No OS Detriment in Lower-Risk MDS

Imetelstat sustained red blood cell (RBC) transfusion independence in patients with RBC transfusion–dependent lower-risk myelodysplastic syndrome.

Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma

Reid W. Merryman, MD, discusses notable advancements with minimal residual disease assays in lymphoma.

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Smith on Bispecific Antibodies for the Management of R/R Follicular Lymphoma

Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.

Dr Giralt on Determining Transplant Eligibility in MDS

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.

Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC